Lorcainide disposition kinetics in arrhythmia patients

@article{Kates1983LorcainideDK,
  title={Lorcainide disposition kinetics in arrhythmia patients},
  author={R. Kates and D. Keefe and R. Winkle},
  journal={Clinical Pharmacology & Therapeutics},
  year={1983},
  volume={33}
}
  • R. Kates, D. Keefe, R. Winkle
  • Published 1983
  • Medicine
  • Clinical Pharmacology & Therapeutics
    • Lorcainide disposition kinetics were studied after intravenous and oral administration to patients with ventricular arrhythmias. After intravenous doses ranging from 100 to 200 mg, blood samples were drawn and plasma was analyzed for lorcainide concentration by high‐pressure liquid chromatography. A three‐compartment model was used to fit the data. The model‐independent calculated values for clearance, steady‐state volume of distribution, and terminal half‐life were 14.4 ± 3.28 ml/min/kg, 6.33… CONTINUE READING
    View on Wiley
    ncbi.nlm.nih.gov
    26 Citations
    Background Citations
    1
    26 Citations
    Citation Type

    Citation Type

    Pharmacodynamics of the initiation of antiarrhythmic therapy with lorcainide.
    • 13
    Intravenous and oral lorcainide: assessment of central nervous system toxicity and antiarrhythmic efficacy.
    • 3
    Pharmacokinetic Implications of Lorcainide Therapy in Patients With Normal and Depressed Cardiac Function
    • 4
    Antiarrhythmic Effect of Lorcainide in Patients Taking Digoxin
    Comparison of the electrophysiologic effects of intravenous and oral lorcainide in patients with recurrent ventricular tachycardia.
    • 24
    • PDF
    Intravenous lorcainide versus lidocaine in the treatment of frequent and complex ventricular arrhythmias.
    • 5
    Chronic lorcainide therapy for symptomatic premature ventricular complexes: efficacy, pharmacokinetics and evidence for norlorcainide antiarrhythmic effect.
    • 10
    Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    • 13
    Initial and long-term outpatient experience with lorcainide for suppression of malignant and potentially malignant ventricular arrhythmias.
    • 6
    Identification of a prazosin metabolite and some preliminary data on its kinetics in hypertensive patients
    • 7

    References

    SHOWING 1-10 OF 11 REFERENCES
    Lorcainide; II. Plasma concentration‐effect relationship
    • 60
    Lorcainide; I. Saturable presystemic elimination
    • 57
    Disposition and antiarrhythmic effect of lorcainide.
    • 29
    Pharmacokinetics of Lorcainide in Man: A New Antiarrhythmic Agent
    • 49
    Pharmacokinetics of lorcainide, a new antiarrhythmic drug, in patients with cardiac rhythm disorders.
    • P. Somani
    • Medicine
    • The American journal of cardiology
    • 1981
    • 30
    A randomized double - blind crossover trial of lorcainide for suppression of symptomatic ventricular arrhythmias
    • Am Heart J
    • 1982
    High-performance liquid chromatographic analysis of lorcainide and its active metabolite, norlorcainide, in human plasma.
    • 14
    Treatment of resistant ventricular arrhythmias by lorcainide , a new antiarrhythmic drug
    • Am J Cardiol
    • 1981
    Noncompartmental determination of the steady-state volume of distribution.
    • 795
    Saturable presystemic elimination
    • CLINT PHARce MACOL THER
    • 1979